Talphera Inc. - Asset Resilience Ratio
Talphera Inc. (TLPH) has an Asset Resilience Ratio of 60.93% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Talphera Inc. (TLPH) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Talphera Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Talphera Inc..
Liquid Assets Composition Over Time
This chart breaks down Talphera Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Talphera Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.33 Million | 60.93% |
| Total Liquid Assets | $16.33 Million | 60.93% |
Asset Resilience Insights
- Very High Liquidity: Talphera Inc. maintains exceptional liquid asset reserves at 60.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Talphera Inc. Industry Peers by Asset Resilience Ratio
Compare Talphera Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Talphera Inc. (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Talphera Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.75% | $14.49 Million | $29.72 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $18.24 Million | -- |
| 2023-12-31 | 17.95% | $3.66 Million | $20.39 Million | +16.90pp |
| 2022-12-31 | 1.04% | $495.00K | $47.49 Million | -48.98pp |
| 2021-12-31 | 50.03% | $38.97 Million | $77.89 Million | +26.48pp |
| 2020-12-31 | 23.55% | $15.61 Million | $66.30 Million | -32.77pp |
| 2019-12-31 | 56.32% | $51.45 Million | $91.36 Million | +41.60pp |
| 2018-12-31 | 14.72% | $17.74 Million | $120.53 Million | +4.70pp |
| 2017-12-31 | 10.02% | $7.57 Million | $75.55 Million | +5.68pp |
| 2015-12-31 | 4.34% | $5.54 Million | $127.78 Million | -13.38pp |
| 2014-12-31 | 17.72% | $15.31 Million | $86.42 Million | +3.85pp |
| 2013-12-31 | 13.87% | $15.26 Million | $110.03 Million | -4.47pp |
| 2012-12-31 | 18.34% | $11.83 Million | $64.52 Million | -50.21pp |
| 2011-12-31 | 68.55% | $27.99 Million | $40.84 Million | +59.37pp |
| 2010-12-31 | 9.18% | $627.00K | $6.83 Million | -28.06pp |
| 2009-12-31 | 37.24% | $5.40 Million | $14.49 Million | -25.09pp |
| 2008-12-31 | 62.33% | $14.13 Million | $22.68 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more